Oligoribonucleotide interference-PCR-based methods for the sensitive and accurate detection of KRAS mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is aggressive with poor outcomes.
• KRAS gene mutations are prevalent in most PDAC cases.
• Liquid biopsy for KRAS mutation detection is promising but faces sensitivity and accuracy challenges.

Purpose of the Study:

• To evaluate oligoribonucleotide interference-PCR (ORNi-PCR) combined with real-time PCR or ddPCR for KRAS mutation detection.
• To assess the sensitivity and accuracy of ORNi-PCR-based methods for liquid biopsy analysis.

Main Methods:

• Utilized a cell-free DNA model system.
• Employed ORNi-PCR followed by real-time PCR.
• Employed ORNi-PCR followed by droplet digital PCR (ddPCR).

Main Results:

• ORNi-PCR-based methods demonstrated superior sensitivity and accuracy compared to conventional real-time PCR and ddPCR.
• The study confirmed the effectiveness of ORNi-PCR in detecting KRAS mutant DNA.

Conclusions:

• ORNi-PCR-based liquid biopsy approaches offer a more sensitive and accurate method for KRAS mutation detection.
• These methods hold potential for the early diagnosis of both new and recurrent pancreatic ductal adenocarcinoma.